Abstract
From May 1994 to February 1995 five HLA-A2 patients affected with melanoma metastases were treated with active immunization with IL4 transfected, irradiated, HLA-A2 + allogeneic melanoma cells. They were injected with 50 × 106 cells at day 1, 13, 26, 55. Two patients received 4 vaccinations, 1 patient 3 vaccinations and 2 patients (actually not evaluables) were injected 2 times. According to the WHO toxicity grading 2 patients presented grade 2 local toxicity and 3 patients had grade 1. No systemic toxicity was recorded. No evidence of clinical response was obtained. At the present, 4 patients are alive with disease and 1 patient is alive without disease after surgical excision of a cutaneous metastasis. From May 1994 to February 1995 five HLA-A2 patients affected with melanoma metastases were treated with active immunization with IL4 transfected, irradiated, HLA-A2 + allogeneic melanoma cells. They were injected with 50 × 106 cells at day 1, 13, 26, 55. Two patients received 4 vaccinations, 1 patient 3 vaccinations and 2 patients (actually not evaluables) were injected 2 times. According to the WHO toxicity grading 2 patients presented grade 2 local toxicity and 3 patients had grade 1. No systemic toxicity was recorded. No evidence of clinical response was obtained. At the present, 4 patients are alive with disease and 1 patient is alive without disease after surgical excision of a cutaneous metastasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
